详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The impact of multidimensional interactions among Helicobacter pylori infection, tumor microenvironment, and gut microbiota on gastric cancer immune response

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China [3]South Sichuan Institute of Translational Medicine, Luzhou, China [4]Research And Experiment Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China [5]Gulin Traditional Chinese Medicine Hospital, Luzhou, China. [6]Infectious Disease Department, The Six School of Clinical Medicine, the Affiliated Qingyuan Hospital ( Qingyuan People's Hospital ), Guangzhou Medical University, No.35, Yinquan North Road, Qingcheng District, Qingyuan, Guangdong, China, 511518.

出处：

DOI：

ISSN：

关键词： H pylori Gastric cancer Immunity Tumor microenvironment Microbiota

摘要：

Helicobacter pylori (H. pylori) infection is a common bacterial disease of the gastric mucosa, affecting more than 40% of the global population, and it is classified by the World Health Organization (WHO) as a Group 1 carcinogen for gastric cancer (GC). H. pylori promotes gastric carcinogenesis through complex molecular mechanisms and modulates host immunity via virulence factors (e.g., CagA and VacA), remodeling of the tumor microenvironment (TME), and substantial effects on the gut microbiota-processes that together influence responses to GC immunotherapy. This review synthesizes the multidimensional interplay among H. pylori, host immune responses, and GC immunotherapy across three domains: virulence factors, TME remodeling, and microbiota dysbiosis. We also highlight emerging therapeutic strategies, including nanotechnology-enabled TME reprogramming, stem-cell engineering to derive immune effector cells, and targeted immunomodulation. These approaches offer mechanistic insights and technical platforms for precision immunotherapy in H. pylori-associated GC and may improve prevention and treatment outcomes.Copyright © 2025. Published by Elsevier B.V.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 3 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 2 区药学

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, China [3]South Sichuan Institute of Translational Medicine, Luzhou, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The role of microRNAs in the gastric cancer tumor microenvironment [2]Metformin-based nanomedicines for reprogramming tumor immune microenvironment [3]Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma [4]Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment [5]Sex bias in tumor immunity: insights from immune cells [6]Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer [7]Gut microbiota in melanoma: Effects and pathogeneses [8]Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy [9]Senescence-related genes define prognosis, immune contexture, and pharmacological response in gastric cancer [10]Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages